Kourtney Kardashian’s Lemme falsely advertises weight loss supplement, class action alleges

Lemme GLP-1 Daily Capsules class action overview:

• Who: A California resident filed two class action lawsuits against Lemme Inc.
• Why: The plaintiff alleges Lemme falsely advertises its Lemme GLP-1 Daily supplement as promoting weight loss.
• Where: The Lemme GLP-1 Daily Capsules class actions were filed in a California state court and New York federal court.

A supplement brand co-founded by one of the famous Kardashian sisters falsely advertises its Lemme GLP-1 Daily supplement as promoting weight loss, two new class action lawsuits allege.

Plaintiff Christina Robins filed the two new class action complaints against Lemme Inc. in a California state court and New York federal court on Feb. 19 and March 9, respectively. 

The complaints bring parallel causes of action under the California and New York consumer fraud statutes against Kourtney Kardashian’s “Lemme GLP-1 Daily,” a GLP-1 weight-loss supplement.

Robins’ class action lawsuits accuse Lemme of misleadingly marketing the supplement, which contains extracts of lemon, orange and saffron, as a cheaper alternative to GLP-1 agonists like Ozempic and Wegovy. GLP-1 agonists are a class of medications designed to treat type-2 diabetes but have also been found to be effective in helping people lose weight, Robins explains.

These medications are expensive, and for those whose insurance does not cover them, they are often cost-prohibitive, the Lemme class actions point out.

“Enter Lemme, a supplement brand founded by Simon Huck and Kourtney Kardashian Barker, hoping to cash in on the GLP-1 agonist craze and swindle Americans into buying their supplements instead,” Robins says.

Lemme GLP-1 Daily falsely claims to promote weight loss, class actions allege

Lemme markets its GLP-1 Daily Capsules as promoting the body’s production of GLP-1, the “un-hunger” hormone, and claims the supplement can help with weight loss, Robins says.

However, the Lemme class action lawsuits allege the company’s claims are based on flawed studies with small sample sizes, and there is no clinical evidence that the supplement’s ingredients have any impact on weight loss.

Robins argues that Lemme’s advertising is misleading because it suggests the supplement can help with weight loss in the same way that GLP-1 agonists do, even though the supplement has not been clinically tested.

The Lemme class action lawsuits seek to represent a nationwide class of consumers and California residents who purchased Lemme GLP-1 Daily from lemmelive.com.

Robins seeks certification of the class action lawsuits, damages, fees, costs and an order enjoining Lemme from continuing its allegedly illegal practices and compelling it to undertake a corrective advertising campaign.

In 2024, Zenwise was hit with a class action lawsuit claiming the company’s over-the-counter Digestive Enzymes and No Bloat supplements do not actually provide the advertised relief.

What do you think of the allegations in these Lemme GLP-1 Daily Capsules class action lawsuits? Let us know in the comments.

The plaintiff in both cases is represented by Thomas D. Warren, Dan Terzian and Erick K. Kuylman of Warren Terzian LLP. The Lemme weight loss class action lawsuits are Robins v. Lemme Inc., Case No. 1:25-cv-01938, in the U.S. District Court for the Southern District of New York and Robins v. Lemme Inc., Case No. 25STCV04635, in the Superior Court of the State of California, County of Los Angeles.

Read About More Class Action Lawsuits & Class Action Settlements:

• McDonald’s class action alleges quarter pounder burgers contain E. coli
• 10 class action settlements you can claim in April 2025
• Tesla announces 8th Cybertruck recall
• Nuna class action alleges Rava car seats unsafe for children